Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000646737 | SCV000768522 | likely benign | Leukocyte adhesion deficiency 3 | 2024-12-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002530483 | SCV003686542 | uncertain significance | Inborn genetic diseases | 2021-07-14 | criteria provided, single submitter | clinical testing | The c.320G>A (p.R107H) alteration is located in exon 3 (coding exon 2) of the FERMT3 gene. This alteration results from a G to A substitution at nucleotide position 320, causing the arginine (R) at amino acid position 107 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV004705750 | SCV005211072 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV004755999 | SCV005353288 | uncertain significance | FERMT3-related disorder | 2024-07-15 | no assertion criteria provided | clinical testing | The FERMT3 c.320G>A variant is predicted to result in the amino acid substitution p.Arg107His. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.13% of alleles in individuals of South Asian descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |